Standard, appropriate, and advanced care and medical-legal considerations: Part one-diabetic foot ulcerations

Wounds

Volumn 15, Issue 4, 2003, Pages 92-106

  Mulder, Gerit ^a   Armstrong, David ^b   Seaman, Susie ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^c SHARP GROSSMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; GROWTH FACTOR; PROCUREN;

ANAMNESIS; CLINICAL TRIAL; DEBRIDEMENT; DIABETIC FOOT; HEALTH CARE QUALITY; HUMAN; INCIDENCE; INFECTION PREVENTION; MEDICAL DOCUMENTATION; MEDICOLEGAL ASPECT; MUSCULOSKELETAL DISEASE; NEUROLOGIC EXAMINATION; NEUROPATHY; PHYSICAL EXAMINATION; REVIEW; SKIN GRAFT; SKIN TRANSPLANTATION; STANDARD; WOUND CARE; WOUND DRESSING;

EID: 0038555668     PISSN: 10447946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. King J. The Law of Medical Malpractice in the State of Washington. St. Paul, MN: West Publishing Co.,1986;52.
2. Consensus Development Conference on Diabetic Foot Wound Care, April 7-9, 1999, Boston, Massachusetts. Diabetes Care, 1999;22(8):1354-60.
3. Frykberg RG, Armstrong DG, Giurini J, et al. Diabetic Foot Disorders: A Clinical Practice Guideline. Brooklandville, MD: Data Trace Publishing Co, 2000.
4. Albrant DH. APhA drug treatment protocols: Management of foot ulcers in patients with diabetes. J APhA 2000;40(4):467-74.
5. McGuckin M, Stineman MG, Goin JE, Williams SV. Venous Leg Ulcer Guideline. Wayne, PA: Health Management Publications Inc, 1997.
6. Bergstom NJ, Bennett MA, Carlson CE, et al. Treatment of pressure ulcers. Clinical Practice Guideline Number 15. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Dept of Health and Human Services, December 1994. ACHPR publication 95-0652.
7. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes impaired fasting gluco glucose and impaired glucose tolerance in US adults. Diabetes Care 1998;21:518-24.
8. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Diabetes Statistics and Prevention and Early Intervention for Diabetes Foot Problems. Bethesda, MD: National Institutes of Health, 1998.
9. Reiber GE, Boyko EJ, Smith DG. Lower-extremity foot ulcers and amputations in diabetes. In: Diabetes in America, Second Edition. Bethesda, MD: National Institutes of Health, 1995:409-28. NIH Publication No. 95-1468.
10. Murray HJ, Boulton AJM. The pathophysiology of diabetic foot ulceration. Clin Podiatr Med Surg 1995;12:1-17.
11. Ehrlichman RJ, Seckel BR, Bryan DJ, Moschella CJ. Common complications of wound healing: Prevention and management. Surg Clin North Am 1991;71:1323-51.
12. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998;21:296-309.
13. Weiman TJ, Smeill JM, Su Y. Efficacy and safety of a topical formulation of a recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care 1998;21:822-7.
14. Coleman WC, Birke JA. The initial foot examination in the patient with diabetes. In: Kominsky SJ (ed). Medical and Surgical Management of the Diabetic Foot. St. Louis, MO: Mosby, 1994;7-27.
15. Caputo GM, Cavanaugh PR, Ulbrecht JS, et al. Assessment and management of foot disease in patients with diabetes. N Engl J Med 1994;331:854-60.
16. Veves A, Sarnow MR. Diagnosis, classification, and treatment of diabetic peripheral neuropathy. Clin Podiatr Med Surg 1995;12:19-30.
17. Armstrong DG, Lavery LA, Velsa SA, et al. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration. Arch Intern Med 1998;158:289-92.
18. Gibbons GW, Marcaccio EJ, Habershaw GM. Management of the diabetic foot. In: Callow AD, Ernst CBN (eds). Vascular Surgery: Theory and Practice. Stamford, CT: Appleton and Lange, 1995;167-78.
19. Hollingshead TS. Pathophysiology and treatment of diabetic foot ulcer. Clin Podiatr Med Surg 1991;8:843-55.
20. Grunfeld C. Diabetic foot ulcers: Etiology, treatment, and prevention. Adv Intern Med 1991;37:103-32.
21. Steed DL. Diabetic wounds: Assessment, classification, and management. In: Krasner D, Kane D (eds). Chronic Wound Care: A Clinical Source Book for Healthcare Professionals, Second Edition. Wayne, PA: Health Management Publications, Inc., 1997;172-7.
22. Arora S, Logerfo FW. Lower-extremity macrovascular disease in diabetes. J Am Podiatr Med Assoc 1997;87:327-31.
23. Lavery LA, Armstrong DG, Vela SA, et al. Practical criteria for screening patients at high risk for diabetic foot ulceration. Arch Intern Med 1998;158:157-62.
24. Simeone LR, Veves A. Screening techniques to identify the diabetic patient at risk of ulceration. J Am Podiatr Assoc 1997;87:313-7.
25. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower-extremity amputation in a diabetic population. Arch Intern Med 1992;152:610-6.
26. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Diabetes Statistics and Prevention and Early Intervention for Diabetes Foot Problems. Bethesda, MD: National Institutes of Health, 1998.
27. Wagner FW. The dysvascular foot: A system for diagnosis and treatment. Foot Ankle 1981;2:64-122.
28. Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic foot wounds. J Foot Ankle Surg 1996;35:528-31.
29. Grayston ML, Gibbons GW, Balogh K, et al. Probing to bone in infected pedal ulcers: A clinical sign underlying osteomyelitis in diabetic patients. J Am Med Assoc 1995;273:721-3.
30. Bowler PG, Davies BJ, Jones SA. Microbial involvement in chronic wound malodour. J Wound Care 1999;8(5):216-8.
31. LeFrock JL, Joseph WS. Bone and soft-tissue infections of the lower extremities in diabetics. Clin Podiatr Med Surg 1995;12:87-103.
32. Little JR, Kobayaashi GS, Bailey TC. Infection of the diabetic foot. In: Levin ME, O'Neal LW, Bowker JH (eds). The Diabetic Foot, Second Edition. St. Louis, MO: Mosby, 1993;181-96.
33. Rodeheaver GT. Wound cleansing, wound irrigation, wound disinfection. In: Krasner D, Kane D (eds). Chronic Wound Care: A Clinical Source Book for Healthcare Professionals, Second Edition. Wayne, PA: Health Management Publications, 1997;97-108.
34. Levin ME. Pathogenesis and management of diabetic foot lesions. In: Levin ME, O'Neal LW, Bowker JH (eds). The Diabetic Foot, Fifth Edition. St. Louis, MO: Mosby, 1993;17-56.
35. Gibbons GW, Eliopoulous GM. Infection of the diabetic foot. In: Kozak GP, Hoar CS, Rowbotham JL, et al (eds). Management of Diabetic Foot Problems. Philadelphia, PA: WB Saunders, 1984;97-102.
36. Steed DL, Donohue D, Webster MW, et al. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg 1996;183:61-4.
37. Boulton AJM. The diabetic foot. Med Clin North Am 1988;72:1513-30.
38. Fleischmsnn E, Grassberger M. Erfolgreiche Wundheilung durch Maden-Therapie. Stuttgart, Germany: TRIAS Verlag, 2002.
39. Ehrlichman RJ, Seckel BR, Bryan DJ, et al. Common complications of wound healing: Prevention and management. Surg Clin North Am 1991;71:1323-51.
40. Janisse DJ. Prescription insoles and footwear. Clin Podiatr Med Surg 1995;12:41-61.
41. Armstrong DG, Lavery LA. Evidence-based options for offloading diabetic wounds. Clin Podiatr Med Surg 1998;15:95-104.
42. Towne JB. Management of foot lesions in the diaheilung patient. In: Rutherford RD (ed). Vascular Surgery, Fourth Edition. Philadelphia, PA: WB Saunders, 1995;895-903.
43. Levin ME. Preventing amputation in the patient with diabetes. Diabetes Care 1995;18:1383-92.
44. Lavery LA, Lavery DC, Quebedeaux-Franham TL. Increased foot pressures after great toe amputation in diabetes. Diabetes Care 1995;18:1460-62.
45. Gilchist B. Infection and culturing. In: Krasner D, Kane D (eds). Chronic Wound Care: A Clinical Source Book for Healthcare Professionals, Second Edition. Wayne, PA: Health Management Publications, Inc., 1997;109-14.
46. Tammellin A, Lindholm C, Hambraeus A. Chronic ulcers and antibiotic treatment. J Wound Care 1998;7(9):435-7.
47. Jensenius M, von der Lippe B, Melby K, Steinbakk M. Proper use of antibiotics: What is that? Tidsskr Nor Laegeforen 1995;115(28):3504-7.
48. Krasner D. Dressing decisions for the twenty-first century: On the cusp of a paradigm shift. In: Krasner D, Kane D (eds). Chronic Wound Care: A Clinical Source Book for Healthcare Professionals, Second Edition. Wayne, PA: Health Management Publications, Inc., 1997;139-51.
49. Seaman S. Dressing selection in chronic wound management. J Am Pod Assoc 2002;92:24-33.
50. Mulder GD, Heberer PA, Jeder KA. Clinician's et Pocket Guide to Wound Repair, Fourth Edition. 1998.
51. Choucair M, Phillips T. A review of wound healing and dressing materials. WOUNDS 1996;8(5):165-72.
52. Turner TD. The development of wound management products. In: Krasner D, Kane D (eds). Chronic Wound Care: A Clinical Source Book for Healthcare Professionals, Second Edition. Wayne, PA: Health Management Publications, Inc., 1997;124-38.
53. Carver N, Leigh IM. Synthetic dressings. Int J Dermatol 1992;31:10-8.
54. Higgins KR, Ashry HR. Wound dressings and topical agents. Clin Podiatr Med Surg 1995;12:31-40.
55. Doughty DB. Principles of wound healing and wound management. In: Bryant RA (ed). Acute and Chronic Wounds: Nursing Management. St. Louis, MO: Mosby, 1992;31-68.
56. Haimowitz JE, Margolis DJ. Moist wound healing. In: Krasner D, Kane D (eds). Chronic Wound Care: A Clinical Source Book for Healthcare Professionals, Second Edition. Wayne PA: Health Management Publications, Inc., 1997;49-56.
57. Hutchinson JJ, McGluckin M. Occlusive dressings: A microbiologic and clinical review. Am J Infec Contr 1990;18:257.
58. Gentzkow GD, Predergast JJ, Iwasaki SD, et al. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996;19:350-4.
59. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs 1997;21:1203-10.
60. Gentzkow GD, Jensen JL, Pollak RA, et al. Improved healing of diabetic foot ulcers after grafting with a living human dermal replacement. WOUNDS 1999;11(3):77-84.
61. Pollak RA, Edington H, Jensen JL. A human dermal replacement for the treatment of diabetic foot ulcers. WOUNDS 1997;9(6):175-83.
62. Parenteau NL, Sabolinski ML, Mulder G, et al. Wound research. In: Krasner D, Kane D (eds). Chronic Wound Care: A Clinical Source Book for Healthcare Professionals, Second Edition. Wayne, PA: Health Management Publications, Inc., 1997;389-95.
63. Pham HT, Rosenblum BI, Lyons TE, et al. Evaluation of a human skin equivalent for the treatment of diabetic foot ulcers in a prospective, randomized, clinical trial. WOUNDS 1999;11(4):79-86.
64. Falanga V, Sabolinski M. A bilayered living skin construct (Apligraf) accelerates complete closure of hard-to-heal venous ulcers. Wound Rep Reg 1999;7:201-7.
65. Knighton DR, Ciresi KF, Fieegel VD, et al. Classification and treatment of chronic nonhealing wounds: Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 1986;204:322-30.
66. Knighton DR, Ciresi K, Fiegel VD, et al. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet 1990;170:56-60.
67. Krupski WC, Reilly LM, Perez S, et al. A prospective randomized trial of autologous platelet-derived wound healing factors for treatment of chronic nonhealing wounds: A preliminary report. J Vasc Surg 1991;14:526-36.
68. Greenhalgh DG. The role of growth factors in wound healing. J Trauma 1996;41:159-67.
69. Lawrence WT, Diegleman RF. Growth factors and wound healing. Dermatol Clin 1994;12:157-69.
70. Shultz GS, Mast BA. Molecular analysis of the environments of healing chronic wounds: Cytokines, proteases, and growth factors. Primary Intention 1999;7(1):7-14.
71. Siihi N. Diabetes and wound healing. J Wound Care 1998;7(1):47-51.
72. REGRANEX (becaplermin) Gel 0.01% product labeling. Raritan, NJ: Ortho-McNeil Pharmaceutical, January, 1998.
73. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg 1995;21:71-81.
74. Weiman TJ, Smiell JM, Su Y. Efficacy and safety of topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. Diabetes Care 1998;21(5):822-7.
75. Pierce PF, Tarpley JE, Yanagihara D, et al. Platelet-derived growth factor (BB homodimer), transforming growth factor-B1, and basic fibroblast growth factor in dermal wound healing. Am J Pathol 1992;140:1375-88.
76. Smiell JM, Wieman JT, Steed DL, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower-extremity diabetic ulcers: A combined analysis of four randomized trials. Wound Rep Reg 1999;7:335-46.
77. Robson MC, Phillips LG, Thomason A, et al. Platelet-derived growth factor BB for the treatment of pressure sores. Lancet 1992;339(8784):23-5.